Multiplexed hormone test for personalizing menopause treatment

Ended Project Grant Awarded Last action

Award ID
R43HD116666
Recipient
Awarding agency
Obligated
$301,299

Award facts

Completion date
Place of performance
Colorado, USA

Award details come from USAspending.gov.

Description

Abstract
Burst diagnostics (BURSTDX), in partnership with femmeloop, is developing a multiplexed, quantitative point-of- care and at-home diagnostic to measure estradiol (E2), progesterone (PG), luteinizing hormone (LH) and follicle stimulating hormone (FSH). The diagnostic will measure levels in blood and saliva to enable determination of perimenopause/ menopause status and personalization of therapies including but not limited to hormone RE- placement therapy (HRT). Perimenopause/menopause affects 27M women in the USA, impacting 20% of the workforce at a cost of $1.8B. Menopause treatment is growing, with the market for diagnostics and treatment currently at $17B. More frequent hormone level checks could be incredibly beneficial for patients and clinicians. However, the current regime for testing is 6-12 months. Consistent, timed daily to weekly tests are required to establish effective treatment but current laboratory testing cannot meet this demand limited by the high costs of testing ($80-$150). At-home multiplexed hormone detection represents an analytical challenge due to the small molecular size and low hormone concentrations in saliva and blood. E2 levels are as low as 1 PG/ML, progester- one levels as low as 10 PG/ML, LH levels as low as 0.5 MIU/ML, and FSH as low as 0.1 MIU/ML. Lateral flow assays (LFAS) and enzyme linked immunosorbent assays (ELISAS) are commercially available but DON't meet the demand. LFAS are easy to use but lack sensitivity and quantitative abilities. Moreover, hormone measure- ments necessitate the use of competitive immunoassays capable of detecting analyte at PG/ML levels, a feat that is virtually unattainable with LFAS. As a result, the market lacks any quantitative LFAS specifically designed for monitoring perimenopause/HRT. As a result, there is a clear need for a new at-home multiplexed test that is easy to use, low cost, accurate, and quantitative. Burst diagnostics (BURSTDX) is developing the capillary-flow driven immunoassay (CADI) as an alternative point-of-care elisa that provides fast, specific, quantitative, multiplexed results. Our goal is to develop a reader that costs

Transactions

Action Obligated Date
Amendment $0
Original award $301,299

Quick answers

Who received award R43HD116666?

R43HD116666 was awarded to Burst Diagnostics Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on September 10, 2025.

How much is award R43HD116666 worth?

$301,299 has been obligated on R43HD116666.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award